Literature DB >> 23639648

Gastrointestinal stromal tumors.

Markku Miettinen1, Jerzy Lasota.   

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the gastrointestinal tract. Soon after GIST was recognized as a tumor driven by a KIT or platelet-derived growth factor receptor mutation, it became the first solid tumor target for tyrosine kinase inhibitor therapies. More recently, alternative molecular mechanisms for GIST pathogenesis have been discovered. These are related to deficiencies in the succinate dehydrogenase complex, NF1-gene alterations in connection with neurofibromatosis type 1 tumor syndrome, and mutational activation of the BRAF oncogene in very rare cases. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23639648      PMCID: PMC3644178          DOI: 10.1016/j.gtc.2013.01.001

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  94 in total

1.  Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases.

Authors:  Yoshihide Otani; Toshiharu Furukawa; Masashi Yoshida; Yoshiro Saikawa; Norihito Wada; Masakazu Ueda; Tetsuro Kubota; Makio Mukai; Kaori Kameyama; Yoshinori Sugino; Koichiro Kumai; Masaki Kitajima
Journal:  Surgery       Date:  2006-04       Impact factor: 3.982

2.  Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.

Authors:  Markku Miettinen; Hala Makhlouf; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2006-04       Impact factor: 6.394

3.  GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology.

Authors:  Jerzy Lasota; Jerzy Stachura; Markku Miettinen
Journal:  Lab Invest       Date:  2006-01       Impact factor: 5.662

4.  NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics.

Authors:  Johanna Andersson; Harri Sihto; Jeanne M Meis-Kindblom; Heikki Joensuu; Nina Nupponen; Lars-Gunnar Kindblom
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

5.  Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).

Authors:  Javier Martín; Andrés Poveda; Antonio Llombart-Bosch; Rafael Ramos; José A López-Guerrero; Javier García del Muro; Joan Maurel; Silvia Calabuig; Antonio Gutierrez; José L González de Sande; Javier Martínez; Ana De Juan; Nuria Laínez; Ferrán Losa; Valentín Alija; Pilar Escudero; Antonio Casado; Paula García; Pilar García; Remei Blanco; José M Buesa
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

Review 6.  PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.

Authors:  Christopher L Corless; Arin Schroeder; Diana Griffith; Ajia Town; Laura McGreevey; Patina Harrell; Sharon Shiraga; Troy Bainbridge; Jason Morich; Michael C Heinrich
Journal:  J Clin Oncol       Date:  2005-05-31       Impact factor: 44.544

7.  Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases.

Authors:  Markku Miettinen; John F Fetsch; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2006-01       Impact factor: 6.394

8.  Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study.

Authors:  Geir Tryggvason; Hjörtur G Gíslason; Magnús K Magnússon; Jón G Jónasson
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

9.  Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.

Authors:  Bengt Nilsson; Per Bümming; Jeanne M Meis-Kindblom; Anders Odén; Aydin Dortok; Bengt Gustavsson; Katarzyna Sablinska; Lars-Gunnar Kindblom
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

10.  PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors.

Authors:  Atsushi Motegi; Shinji Sakurai; Hiroko Nakayama; Takaaki Sano; Tetsunari Oyama; Takashi Nakajima
Journal:  Pathol Int       Date:  2005-03       Impact factor: 2.534

View more
  83 in total

1.  New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.

Authors:  Jerzy Lasota; Artur Kowalik; Anna Felisiak-Golabek; Sebastian Zięba; Zeng-Feng Wang; Markku Miettinen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2019-01

2.  Technical success and short-term results of surgical treatment of gastrointestinal stromal tumors: an experience of three centers.

Authors:  Mark Igorevich Gluzman; Victor Anatolevich Kashchenko; Aleksei Mikhailovich Karachun; Rashida Vakhidovna Orlova; Iakov Aleksandrovich Nakatis; Iurii Vasilevich Pelipas; Evgenia Leonidovna Vasiukova; Ivan Vladimirovich Rykov; Veronika Vladimirovna Petrova; Svetlana Leonidovna Nepomniashchaia; Anton Sergeevich Klimov
Journal:  Transl Gastroenterol Hepatol       Date:  2017-06-02

3.  Spontaneous leiomyomas of the gastroesophageal junction in a chimpanzee (Pan troglodytes).

Authors:  Sanjeev Gumber; Melissa I Stovall; Eileen Breding; Maria M Crane
Journal:  Comp Med       Date:  2014-06       Impact factor: 0.982

Review 4.  The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.

Authors:  Sosipatros A Boikos; Constantine A Stratakis
Journal:  Endocrine       Date:  2014-07-16       Impact factor: 3.633

5.  Head of the pancreas mass that turned out to be not a pancreatic cancer.

Authors:  Tetyana McIlvaine; Colin Kenny; Franklin Goldwire; Kyler Kozacek
Journal:  BMJ Case Rep       Date:  2019-04-20

6.  Our Experience Regarding the Association Between Gastrointestinal Stromal Tumor and Bariatric Surgery: a Response to a Letter "Gastrointestinal Stromal Tumor After Laparoscopic Sleeve Gastrectomy: Be Awake Before, During, and After a Bariatric Procedure".

Authors:  Hubert Johanet; Fabien Mantilla-Sylvain; André Dabrowski; Franck Maisonnette; Robert Portet; Olivier Merlier; Philippe Malvaux
Journal:  Obes Surg       Date:  2019-02       Impact factor: 4.129

Review 7.  Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.

Authors:  Matt Shirley; Gillian M Keating
Journal:  Drugs       Date:  2015-06       Impact factor: 9.546

8.  Immunostaining of phospho-histone H3 and Ki-67 improves reproducibility of recurrence risk assessment of gastrointestinal stromal tumors.

Authors:  Arnaud Uguen; Gwenaël Conq; Laurent Doucet; Matthieu Talagas; Sebastian Costa; Marc De Braekeleer; Pascale Marcorelles
Journal:  Virchows Arch       Date:  2015-04-01       Impact factor: 4.064

Review 9.  Management of liver metastases from gastrointestinal stromal tumors: where do we stand?

Authors:  Nikolaos Machairas; Anastasia Prodromidou; Ernesto Molmenti; Ioannis D Kostakis; Georgios C Sotiropoulos
Journal:  J Gastrointest Oncol       Date:  2017-12

10.  Prognostic factors of primary gastrointestinal stromal tumors: a cohort study based on high-volume centers.

Authors:  Xuechao Liu; Haibo Qiu; Peng Zhang; Xingyu Feng; Tao Chen; Yong Li; Kaixiong Tao; Guoxin Li; Xiaowei Sun; Zhiwei Zhou
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.